Dynavax Technologies Co. (DVAX) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. increased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 8.2% in the 4th quarter, Holdings Channel reports. The firm owned 1,058,630 shares of the biopharmaceutical company’s stock after acquiring an additional 79,900 shares during the quarter. Franklin Resources Inc.’s holdings in Dynavax Technologies were worth $19,796,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Schwab Charles Investment Management Inc. lifted its position in shares of Dynavax Technologies by 29.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 235,310 shares of the biopharmaceutical company’s stock worth $5,060,000 after purchasing an additional 54,149 shares during the last quarter. Swiss National Bank lifted its position in shares of Dynavax Technologies by 40.7% during the 3rd quarter. Swiss National Bank now owns 99,878 shares of the biopharmaceutical company’s stock worth $2,147,000 after purchasing an additional 28,900 shares during the last quarter. First Republic Investment Management Inc. acquired a new position in shares of Dynavax Technologies during the 3rd quarter worth about $2,414,000. Bank of New York Mellon Corp lifted its position in shares of Dynavax Technologies by 43.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 359,650 shares of the biopharmaceutical company’s stock worth $7,733,000 after purchasing an additional 108,788 shares during the last quarter. Finally, Senvest Management LLC lifted its position in shares of Dynavax Technologies by 29.3% during the 4th quarter. Senvest Management LLC now owns 1,541,588 shares of the biopharmaceutical company’s stock worth $28,828,000 after purchasing an additional 349,288 shares during the last quarter. 71.22% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

DVAX stock opened at $18.50 on Friday. Dynavax Technologies Co. has a twelve month low of $5.00 and a twelve month high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.32). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.53 million. Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 57.43%. equities analysts forecast that Dynavax Technologies Co. will post -1.91 EPS for the current fiscal year.

Several equities analysts recently weighed in on DVAX shares. Royal Bank of Canada reissued a “buy” rating and set a $25.00 price objective on shares of Dynavax Technologies in a research report on Friday, March 9th. BidaskClub cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $27.00 price objective (up previously from $25.00) on shares of Dynavax Technologies in a research report on Thursday, March 8th. Cowen reissued a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, February 21st. Finally, ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $24.67.

In other Dynavax Technologies news, insider David F. Novack sold 34,214 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $16.52, for a total value of $565,215.28. Following the completion of the transaction, the insider now owns 21,613 shares of the company’s stock, valued at approximately $357,046.76. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David F. Novack sold 16,109 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $16.30, for a total value of $262,576.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,536 shares of company stock valued at $923,418. Insiders own 2.90% of the company’s stock.

WARNING: “Dynavax Technologies Co. (DVAX) Shares Bought by Franklin Resources Inc.” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3295419/dynavax-technologies-co-dvax-shares-bought-by-franklin-resources-inc.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barrick Gold  Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPS
Barrick Gold Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Moelis & Company  Posts Quarterly  Earnings Results, Beats Expectations By $0.25 EPS
Moelis & Company Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS
Zacks: Brokerages Expect Apple  to Post $2.69 Earnings Per Share
Zacks: Brokerages Expect Apple to Post $2.69 Earnings Per Share
$0.26 EPS Expected for MoneyGram International Inc  This Quarter
$0.26 EPS Expected for MoneyGram International Inc This Quarter
Analyzing Target  & Its Competitors
Analyzing Target & Its Competitors
Critical Comparison: Ascena Retail Group  vs. Vince
Critical Comparison: Ascena Retail Group vs. Vince


© 2006-2018 Ticker Report. Google+.